Profile data is unavailable for this security.
About the company
Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets medical device products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. The Company's segments include New Zealand, which includes all activities controlled by entities or employees based in New Zealand; North America, which includes all activities controlled by entities or employees based in the United States and Canada; Europe, which includes all activities controlled by entities or employees based in the United Kingdom, France, Germany, Sweden, Turkey and Russia, and Asia-Pacific, which includes all activities controlled by entities or employees based in Australia, Japan, India, China, South Korea, Taiwan and Hong Kong. Its products include respiratory humidifiers, single-use and reusable chambers and breathing circuits, infant resuscitators, infant warmers and accessories. In addition, the Company offers hardware and consumables.
- Revenue in NZD (TTM)1.07bn
- Net income in NZD209.20m
- Incorporated1954
- Employees4.55k
- LocationFisher & Paykel Healthcare Corporation Ltd15 Maurice Paykel Place, East TamakiAUCKLAND 1061New ZealandNZL
- Phone+64 95740100
- Fax+64 95740158
- Websitehttps://www.fphcare.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China National Medicines Corporation Ltd | 9.08bn | 337.31m | 4.84bn | 2.86k | 14.37 | 2.26 | -- | 0.5333 | 1.99 | 1.99 | 53.58 | 12.67 | 1.93 | 11.92 | 4.07 | 14,347,500.00 | 8.18 | 8.31 | 18.51 | 19.64 | 8.30 | 7.93 | 4.24 | 3.88 | 1.56 | -- | 0.1341 | 18.59 | 6.77 | 30.90 | 23.01 | 27.82 | 1.72 | 9.00 |
| Hartalega Holdings Berhad | 1.04bn | 159.80m | 6.67bn | 7.70k | 41.92 | 7.66 | 33.17 | 6.41 | 0.1257 | 0.1257 | 0.8182 | 0.6884 | 0.9566 | -- | 7.28 | 358,567.10 | 14.69 | 15.84 | 17.11 | 18.24 | -- | 26.36 | 15.36 | 16.97 | 1.74 | 47.00 | 0.1311 | 53.54 | 17.52 | 20.62 | 3.70 | 14.35 | 17.09 | 17.73 |
| Shandong Weigao Group Medical Polymer Co | 2.13bn | 390.05m | 7.83bn | 9.56k | 19.89 | 2.28 | 14.48 | 3.68 | 0.4339 | 0.4339 | 2.37 | 3.78 | 0.4031 | 3.16 | 2.40 | 1,109,876.00 | 7.68 | 8.04 | 9.31 | 9.69 | 62.74 | 61.34 | 19.04 | 19.09 | 2.52 | 9.11 | 0.257 | 31.21 | 39.99 | 13.81 | 17.34 | 30.58 | -4.74 | 28.11 |
| Fisher & Paykel Healthcare Corp Ltd | 1.07bn | 209.20m | 9.50bn | 4.55k | 45.73 | 10.39 | 37.86 | 8.87 | 0.3619 | 0.3619 | 1.85 | 1.59 | 0.9592 | 2.71 | 7.04 | 235,408.00 | 18.75 | 19.38 | 22.39 | 23.50 | 66.87 | 65.17 | 19.54 | 18.61 | 1.73 | 225.71 | 0.0863 | 65.01 | 9.14 | 11.42 | 9.99 | 16.60 | 33.13 | 15.63 |
| ASAHI INTECC CO., LTD. | 830.13m | 163.04m | 9.71bn | 7.00k | 59.71 | 10.23 | 45.76 | 11.70 | 43.05 | 43.05 | 219.14 | 251.39 | 0.7314 | 1.36 | 5.99 | -- | 14.37 | 13.90 | 17.10 | 17.06 | 69.39 | 67.19 | 19.64 | 18.56 | 2.52 | 41.82 | 0.0842 | 25.08 | 14.15 | 15.25 | 11.91 | 20.85 | 34.55 | 20.51 |
| Cochlear Limited | 1.54bn | 298.44m | 13.20bn | 4.00k | 44.15 | 16.83 | 38.82 | 8.58 | 4.79 | 4.79 | 24.72 | 12.58 | 1.13 | 1.90 | 4.48 | 356,675.00 | 21.82 | 20.87 | 29.30 | 29.73 | 75.85 | 73.16 | 19.39 | 17.82 | 1.22 | -- | 0.2001 | 69.81 | 4.62 | 12.13 | 9.76 | 24.18 | 29.11 | 5.37 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 13 Dec 2018 | 30.15m | 5.25% |
| Capital Research & Management Co. (World Investors)as of 30 Jun 2019 | 23.97m | 4.18% |
| BlackRock Fund Advisorsas of 19 Mar 2019 | 18.79m | 3.27% |
| Accident Compensation Corp.as of 30 Apr 2018 | 13.92m | 2.43% |
| Guardians of New Zealand Superannuationas of 30 Jun 2018 | 13.90m | 2.42% |
| Fidelity Management & Research Co.as of 31 Jul 2019 | 9.18m | 1.60% |
| T. Rowe Price International Ltd.as of 30 Jun 2019 | 6.97m | 1.21% |
| Norges Bank Investment Managementas of 31 Dec 2018 | 6.41m | 1.12% |
| Capital Research & Management Co. (Global Investors)as of 30 Jun 2019 | 4.46m | 0.78% |
| Australian Foundation Investment Co. Ltd. (Invt Mgmt)as of 30 Jun 2019 | 3.81m | 0.66% |
